Glass House Brands (GLAS) Other Non-Current Liabilities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Other Non-Current Liabilities of $36.0 million for Q1 2026, up 42.67% year-over-year from $25.3 million in Q1 2025, and up 7.85% quarter-over-quarter from $33.4 million in Q4 2025.
Glass House Brands (GLAS) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Other Non-Current Liabilities for 7 consecutive years, with $36.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 42.67% year-over-year to $36.0 million; the TTM figure through Mar 2026 stood at $36.0 million (up 42.67% YoY), while the FY2025 annual figure was $33.4 million, up 60.11% from the prior year.
- Other Non-Current Liabilities advanced to $36.0 million in Q1 2026 per GLAS's latest filing, from $33.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $19099.7 billion in Q2 2023 and bottomed at -$6314.2 billion in Q2 2022.
- Historically, Other Non-Current Liabilities has averaged $752.1 billion across 5 years, with a median of $20.9 million in 2024.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 3808.88% in 2022 and fell as far as 179.32% in 2022.
- Glass House Brands' Other Non-Current Liabilities stood at $14.7 million in 2022, then soared by 136.0% to $34.6 million in 2023, then plunged by 39.67% to $20.9 million in 2024, then jumped by 60.11% to $33.4 million in 2025, then rose by 7.85% to $36.0 million in 2026.
- Business Quant data shows GLAS's Other Non-Current Liabilities at $36.0 million in Q1 2026, $33.4 million in Q4 2025, and $31.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Glass House Brands | 825.81 Mn | 807.26 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.04 Mn |
| Dec 31, 2025 | 33.41 Mn |
| Sep 30, 2025 | 31.60 Mn |
| Jun 30, 2025 | 28.24 Mn |
| Mar 31, 2025 | 25.26 Mn |
| Dec 31, 2024 | 20.87 Mn |
| Sep 30, 2024 | 20.19 Mn |
| Jun 30, 2024 | -7.91 Mn |
| Mar 31, 2024 | 5.97 Mn |
| Dec 31, 2023 | 34.59 Mn |
| Sep 30, 2023 | 18.49 Mn |
| Jun 30, 2023 | 19,099.75 Bn |
| Mar 31, 2023 | 4.88 Mn |
| Dec 31, 2022 | 14.66 Mn |
| Sep 30, 2022 | -31.12 Mn |
| Jun 30, 2022 | -6,314.19 Bn |
| Mar 31, 2022 | 44.91 Mn |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 39.24 Mn |
| Mar 31, 2021 | 1.15 Mn |